The antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has been approved in the USA, for the treatment of certain adults with unresectable or metastatic HER2-positive breast cancer.
Developed by AstraZeneca (LSE: AZN) and Daiichi Sankyo (TYO: 4568), the therapy has been granted approval for people who have already received a prior anti-HER2-based regimen.
The decision was based on positive results from the Phase III DESTINY-Breast03 trial, which showed Enhertu reduced the risk of disease progression or death by 72%, compared with Roche’s (ROG: SIX) Kadcyla (trastuzumab emtansine).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze